CHAIN Announces Academic Collaboration
CHAIN is pleased to announce a new 18-month research collaboration with Associate Professor John Heap and his research group at the University of Nottingham. Dr Heap is Associate Professor of Synthetic Biology in the School of Life Sciences at the University of Nottingham, where he is also part of the newly-formed Biodiscovery Institute […]
CHAIN Biotech appoints Dr Andrew Morgan as Chief Scientific Adviser
Andrew has had a distinguished career at Danisco/DuPont, acting as Chief Scientific Officer (2008–2011) for Danisco and Chief Scientist for DuPont Nutrition & Health (2011–2019). He was appointed a DuPont Fellow in 2016 and played a key role in helping build DuPont’s microbiome platform. Having retired from DuPont at the end of 2019, […]
CHAIN features in Genetic Engineering & Biotechnology News (GEN)
”An expansive view of design has been adopted at CHAIN Biotechnology, which is developing new therapeutics based on living microbes where the “bug is the drug.” These drugs are based on a single strain of Clostridium bacteria that is naturally found in the gut, but which has been deliberately engineered to carry a therapeutic payload, such as […]
Superior and effective microbiome therapeutics
About us
CHAIN Biotechnology Ltd is a microbiome therapeutics company with a novel drug development platform targeting chronic gut-related diseases.
Platform
Our Clostridium Assisted Drug Development (CADD™) platform provides superior gut delivery to support a pipeline of drug candidates addressing multiple therapeutic areas associated with the gut microbiome.
Clinical Focus
We target inflammatory bowel disease with a focus on Ulcerative Colitis. Our lead drug candidate is a live biotherapeutic engineered to produce anti-inflammatory metabolites; β-hydroxybutyrate and butyrate.